Close Menu

J&J

Veracyte plans to launch a new version of its Percepta test and present data for a nasal swab lung cancer diagnostic this year.

It anticipates using the funds to complete the development of its first set of diagnostic products, and for a set of clinical studies to obtain regulatory clearance.

As part of the collaboration, Johnson & Johnson will build a lung cancer center at Boston University and build upon programs linked to cancer research.


The deal follows the release of a report that, among other things, urged support for genomics and other life sciences in the UK.

The firm’s emphasis on automation has yielded Dx products for blood banks, assays for HIV and acute kidney injury, and flexible diagnostic test systems that can adapt to labs’ changing needs.

The companies will work to develop an affordable, portable, and easy-to-use HIV quantitative viral load test using Cue's Lab-In-A-Box MDx platform.

Johnson & Johnson announced that it would be cutting about 3,000 jobs from its medical devices section.

Using J&J's CellSearch platform, researchers have demonstrated the expression of PD-L1 on CTCs, a finding they believe they are the first to show.

Three new assays were presented in posters at April's Clinical Virology Symposium.

Pages

US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.

Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.

Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.

In Science this week: almond reference genome, and more.